Second, matched therapy targeting the activated PI3K/AKT/mTOR pathway in patients with metastatic or recurrent squamous cell carcinoma of the cervix led to a favorably higher rate of SD ≥ 6 months/CR/PR as well as significantly longer PFS and OS than non-matched therapy. This evidence concerns the gene MTOR and cervical squamous cell carcinoma.